Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

1 terminated/withdrawn out of 2 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
1(50.0%)
Early Phase 1
1(50.0%)
2Total
Phase 1(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2)

Showing 2 of 2 trials
NCT07052760Early Phase 1Withdrawn

Imaging of Solid Tumors Using DLL3 SPECT

Role: collaborator

NCT06736418Phase 1Active Not Recruiting

Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy

Role: lead

All 2 trials loaded